Eficacitatea medicaței cu soluție „Solcoseril” la pacienți cu insuficiență arterială de geneză aterosclerotică

Abstract

Scopul terapiei medicamentoase a ischemiei cronice de geneză aterosclerotică este ameliorarea situației metabolice prin înlăturarea acidozei tisulare, stimulării metabolizmului de oxido-reducere stimulării activității mitocondriale. De menționat faptul că efectele metabolice nu depind de ameliorarea microcirculației locale ci de modificările metabolice la nivel celular. Astfel de efect polivalent posedă preparatul Solcoseril obținut din săngele vițeilor. Materiale şi metode: S-a efectuat evaluarea clinică a monoterapiei cu soluție 20% Solcoseril la pacienți cu insuficiență arterială de geneză aterosclerotică, apoi terapiea de susținere ulterioară cu pastille. S-au examinat 68 pacienți {61 bărbați şi 7 femei}. Vărsta medie 65,3ani {de la 42 pănă la 74 ani}. Durata patologiei în mediu 3,4 ani. Toți pacienții erau in stadiu 2b {clasificarea Fontaine}. Simptomele clinice erau: - hipotermie în extremități - 87%, -Parastezia extremităților - 95%, -Limitarea funcției de diferit grad a extremităților - 100%. Diagnosticul clinic s- a confirmat prin prezența claudicatiei intermitente şi Doppler a arterelor membrelor inferioare. Toți pacienții au fost clasați in 2 loturi: A - cu claudicație intermetrentă inițială, parcurgera distanței mai mult de 100 metri, B - mai puțin de 100 metri. Tratamentul: Toți pacienții pe parcursul 15 zile cotidian intravenos in perfuzie au primit soluție 25% - 250 ml „Solcoseril” in condiții de staționar de zi. Apoi sa efectuat o cură de o luna de zile terapie de susținere cu „Solcoseril”- pastile, 1 pastilă {200mg} 3 ori in zi. Rezultatele: La finele tratamentului majorarea in mediu a distanței claudicației intermitrente a fost - 54.5%, in lotul A - 37%, lotul B - 74%. Subiectiv – 93% de pacienți au atestat ameliorarea starii. Examinarea pacienților peste 3 şi 6 luni după tratament a constatat majorarea distanței parcurse statistic demonstrat.

The scope of drug therapy against chronic ischemia of atherosclerotic genesis is to improve the metabolic situation, with the elimination of tissue acidosis by stimulating oxidative metabolism, mitochondria activity, increase the production of high-energy phosphates. It should be noted that these metabolic effects are not associated with increased blood flow, but due to improved metabolic situation at the cellular level. Thus polyvalent action has the drug “Solcoseryl”, deproteinized hemodialysis obtained from the blood of young calves. Materials and methods: Was carried out a comprehensive clinical evaluation of the effectiveness of monotherapy with 20% solution Solcoseryl in patients with chronic arterial insufficiency of the lower extremities of atherosclerotic genesis, followed by maintenance therapy with “Solcoseryl” pills. The study included 68 patients (61 men and 7 women). The average patient age was 56.3 years (range 42 to 74 years). Duration of disease - an average of 3.4 years (range 19 months to 9 years). All patients had stage 2b disease (classification of Fontaine). The characteristic symptoms were: feeling cold (chill) in the limbs - 87% of patients, paraesthesias of the limbs - 95% of patients limited in walking - various degrees - at 100%. Clinical diagnosis was confirmed by the presence of symptoms of intermittent claudication for the sample on the treadmill test, Doppler of lower limb arteries. All the subjects were divided into 2 subgroups: q subgroup A with the IC when passing over a distance of 100 meters; q subgroup B with the IC at a distance of fewer than 100 meters. Treatment: All patients have received a 15-day course of daily i/v perfusion with 250 ml 20% solution of «Solcoseryl» in conditions of a day hospital. All patients have also received a monthly support therapy with «Solcoseryl” tablets, 1 tablet (200 mg) 3 times per. Results: By the end of therapy the average increase in distance of intermittent claudication was registered as high as 54.5%, while in group A, the result was 37%, and in group B - 74%. Control examination and clinical examination of patients in 3 and 6 months after treatment showed that the subgroups A and B had a statistically significant increase in maximum walking distance, compared with the results reached at the end of treatment.